PANACEABIO

Panacea Biotec Share Price

₹414.35 -14.7 (-3.43%)

08 Feb, 2025 03:51

SIP TrendupStart SIP in PANACEABIO

Start SIP

Performance

  • Low
  • ₹400
  • High
  • ₹427
  • 52 Week Low
  • ₹112
  • 52 Week High
  • ₹491
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month -6.81%
  • Over 3 Month + 5.38%
  • Over 6 Month + 212.48%
  • Over 1 Year + 157.6%
SIP Lightning

Smart Investing Starts Here Start SIP with Panacea Biotec for Steady Growth!

Invest Now

Panacea Biotec Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Panacea Biotec Financials

Panacea Biotec Technicals

EMA & SMA

Current Price
₹414.35
-14.7 (-3.43%)
pointer
  • stock-down_img
  • Bearish Moving Average 1
  • stock-up_img
  • Bullish Moving Average 15
  • 20 Day
  • ₹387.37
  • 50 Day
  • ₹395.01
  • 100 Day
  • ₹366.32
  • 200 Day
  • ₹306.62

Resistance and Support

413.77 Pivot Speed
  • R3 454.18
  • R2 440.52
  • R1 427.43
  • S1 400.68
  • S2 387.02
  • S3 373.93

What's your outlook on Panacea Biotec?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Panacea Biotec is a biotechnology company specializing in research, development, and manufacturing of vaccines, pharmaceuticals, and biosimilars. It operates state-of-the-art facilities in India, serving global markets across North America, Europe, and emerging economies.

Panacea Biotec (Nse) has an operating revenue of Rs. 550.03 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 0% needs improvement, ROE of -0% is poor and needs improvement. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 59% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 12% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 30 which is a POOR score indicating inconsistency in earnings, a RS Rating of 96 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 59 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Panacea Biotec Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-14 Quarterly Results
2024-11-13 Quarterly Results
2024-08-14 Quarterly Results
2024-05-30 Audited Results
2024-02-13 Quarterly Results

Panacea Biotec F&O

Panacea Biotec Shareholding Pattern

72.49%
0.38%
18.98%
8.15%

About Panacea Biotec

  • NSE Symbol
  • PANACEABIO
  • BSE Symbol
  • 531349
  • Chairman & Managing Director
  • Dr. Rajesh Jain
  • ISIN
  • INE922B01023

Similar Stocks to Panacea Biotec

Panacea Biotec FAQs

Panacea Biotec share price is ₹414 As on 08 February, 2025 | 03:37

The Market Cap of Panacea Biotec is ₹2537.9 Cr As on 08 February, 2025 | 03:37

The P/E ratio of Panacea Biotec is -173.5 As on 08 February, 2025 | 03:37

The PB ratio of Panacea Biotec is 3 As on 08 February, 2025 | 03:37

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23